Premium
EPA with antidepressant did not improve treatment efficacy in cardiac patients
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30472
Subject(s) - sertraline , antidepressant , medicine , placebo , eicosapentaenoic acid , major depressive disorder , randomized controlled trial , depressive symptoms , placebo group , psychiatry , alternative medicine , cognition , fatty acid , polyunsaturated fatty acid , chemistry , organic chemistry , pathology , amygdala , hippocampus
Augmenting sertraline with eicosapentaenoic acid (EPA) for 10 weeks did not improve depressive symptoms relative to placebo in a group of 144 patients with major depressive disorder and existing or high risk of heart disease, a randomized trial has found. These results were inconsistent with findings of previous research showing that EPA supplementation improved the efficacy of standard antidepressant treatment.